{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:45Z","timestamp":1790957685243,"version":"4.1.0"},"reference-count":34,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Invasive micropapillary carcinoma (IMPC) is a rare variant of breast carcinoma, composed of avascular morula-like tumor clusters surrounded by stromal spaces, which can affect the HER2 immunohistochemical (IHC) staining pattern. The 2013 American Society of Clinical Oncology\/College of American Pathologists (ASCO\/CAP) HER2 testing guideline suggests moderate to intense but incomplete (basolateral) staining be considered equivocal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives.\u2014<\/jats:title>\n                    <jats:p>To perform a detailed assessment of HER2 IHC staining patterns in IMPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Hematoxylin-eosin and HER2 IHC slides were retrospectively reviewed to assess the morphology and HER2 IHC characteristics of IMPC. The 2018 ASCO\/CAP guideline was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>The cohort consisted of 187 IMPCs from 181 patients with median age of 58 years. Homogeneous (\u226590%) micropapillary component was found in 40% (75 of 187) of cases. Receptor profile was as follows: 75% (140 of 187) ER+ HER2\u2212, 19% (37 of 187) ER+ HER2+, 4% (7 of 187) ER\u2212 HER2+, and 2% (3 of 187) ER\u2212 HER2\u2212. Of 26 cases with HER2 IHC 3+, 65% (17 of 26) showed a basolateral staining pattern with strong intensity. HER2 fluorescence in situ hybridization (FISH) showed amplification in 26% (17 of 66) of HER2 IHC equivocal cases: 76% (13 of 17) showed basolateral staining pattern and 24% (4 of 17) complete staining, with weak to moderate (2), moderate (14), or moderate to strong (1) intensity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The most frequent staining pattern was basolateral, seen in 49% of cases, including 65% HER2 IHC positive and 76% HER2 IHC equivocal\/FISH amplified. If a basolateral pattern and weak to moderate staining is observed in IMPC, alternative testing should be performed to confirm the HER2 status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2020-0288-oa","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T21:28:52Z","timestamp":1605907732000},"page":"979-987","source":"Crossref","is-referenced-by-count":15,"title":["HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern"],"prefix":"10.5858","volume":"145","author":[{"given":"Marjorie","family":"Perron","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Hanna","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"2021080319422280700_i1543-2165-145-8-979-b01","unstructured":"Allison\n              KH,\n            \n            \n              Brogi\n              E,\n            \n            \n              Ellis\n              IO,\n            \n            et al.\n          \n          \n            WHO Classification of Breast Tumours. 5th ed.\n\t\t\t\t\tLyon, France:\n\t\t\t\t\tInternational Agency for Research on Cancer (IARC);2019.\n\t\t\t\t\tWorld Health Organization Classification of Tumours; vol 2."},{"key":"2021080319422280700_i1543-2165-145-8-979-b02","unstructured":"Siriaunkgul\n              S,\n            \n            \n              Tavassoli\n              FA.\n            \n          \n          Invasive micropapillary carcinoma of the breast.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t1993;\n\t\t\t\t\t6(6):\n\t\t\t\t\t660\u2013\n\t\t\t\t\t662."},{"key":"2021080319422280700_i1543-2165-145-8-979-b03","doi-asserted-by":"crossref","unstructured":"Marchio\n              C,\n            \n            \n              Iravani\n              M,\n            \n            \n              Natrajan\n              R,\n            \n            et al.\n          \n          Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.\n\t\t\t\t\tJ Pathol.\n\t\t\t\t\t2009;\n\t\t\t\t\t218(3):\n\t\t\t\t\t301\u2013\n\t\t\t\t\t315.","DOI":"10.1002\/path.2572"},{"key":"2021080319422280700_i1543-2165-145-8-979-b04","doi-asserted-by":"crossref","unstructured":"Marchio\n              C,\n            \n            \n              Iravani\n              M,\n            \n            \n              Natrajan\n              R,\n            \n            et al.\n          \n          Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.\n\t\t\t\t\tJ Pathol.\n\t\t\t\t\t2008;\n\t\t\t\t\t215(4):\n\t\t\t\t\t398\u2013\n\t\t\t\t\t410.","DOI":"10.1002\/path.2368"},{"key":"2021080319422280700_i1543-2165-145-8-979-b05","doi-asserted-by":"crossref","unstructured":"Tang\n              SL,\n            \n            \n              Yang\n              JQ,\n            \n            \n              Du\n              ZG,\n            \n            et al.\n          \n          Clinicopathologic study of invasive micropapillary carcinoma of the breast.\n\t\t\t\t\tOncotarget.\n\t\t\t\t\t2017;\n\t\t\t\t\t8(26):\n\t\t\t\t\t42455\u2013\n\t\t\t\t\t42465.","DOI":"10.18632\/oncotarget.16405"},{"key":"2021080319422280700_i1543-2165-145-8-979-b06","doi-asserted-by":"crossref","unstructured":"Vingiani\n              A,\n            \n            \n              Maisonneuve\n              P,\n            \n            \n              Dell'orto\n              P,\n            \n            et al.\n          \n          The clinical relevance of micropapillary carcinoma of the breast: a case-control study.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2013;\n\t\t\t\t\t63(2):\n\t\t\t\t\t217\u2013\n\t\t\t\t\t224.","DOI":"10.1111\/his.12147"},{"key":"2021080319422280700_i1543-2165-145-8-979-b07","doi-asserted-by":"crossref","unstructured":"Chen\n              AC,\n            \n            \n              Paulino\n              AC,\n            \n            \n              Schwartz\n              MR,\n            \n            et al.\n          \n          Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast.\n\t\t\t\t\tBr J Cancer.\n\t\t\t\t\t2014;\n\t\t\t\t\t111(3):\n\t\t\t\t\t619\u2013\n\t\t\t\t\t622.","DOI":"10.1038\/bjc.2014.301"},{"key":"2021080319422280700_i1543-2165-145-8-979-b08","doi-asserted-by":"crossref","unstructured":"Yamaguchi\n              R,\n            \n            \n              Tanaka\n              M,\n            \n            \n              Kondo\n              K,\n            \n            et al.\n          \n          Characteristic morphology of invasive micropapillary carcinoma of the breast: an immunohistochemical analysis.\n\t\t\t\t\tJpn J Clin Oncol.\n\t\t\t\t\t2010;\n\t\t\t\t\t40(8):\n\t\t\t\t\t781\u2013\n\t\t\t\t\t787.","DOI":"10.1093\/jjco\/hyq056"},{"key":"2021080319422280700_i1543-2165-145-8-979-b09","doi-asserted-by":"crossref","unstructured":"Badyal\n              RK,\n            \n            \n              Bal\n              A,\n            \n            \n              Das\n              A,\n            \n            \n              Singh\n              G.\n            \n          \n          Invasive micropapillary carcinoma of the breast: immunophenotypic analysis and role of cell adhesion molecules (CD44 and E-Cadherin) in nodal metastasis.\n\t\t\t\t\tAppl Immunohistochem Mol Morphol.\n\t\t\t\t\t2016;\n\t\t\t\t\t24(3):\n\t\t\t\t\t151\u2013\n\t\t\t\t\t158.","DOI":"10.1097\/PAI.0000000000000167"},{"key":"2021080319422280700_i1543-2165-145-8-979-b10","doi-asserted-by":"crossref","unstructured":"Kuroda\n              H,\n            \n            \n              Sakamoto\n              G,\n            \n            \n              Ohnisi\n              K,\n            \n            \n              Itoyama\n              S.\n            \n          \n          Overexpression of Her2\/neu, estrogen and progesterone receptors in invasive micropapillary carcinoma of the breast.\n\t\t\t\t\tBreast Cancer.\n\t\t\t\t\t2004;\n\t\t\t\t\t11(3):\n\t\t\t\t\t301\u2013\n\t\t\t\t\t306.","DOI":"10.1007\/BF02984553"},{"key":"2021080319422280700_i1543-2165-145-8-979-b11","doi-asserted-by":"crossref","unstructured":"Liu\n              F,\n            \n            \n              Yang\n              M,\n            \n            \n              Li\n              Z,\n            \n            et al.\n          \n          Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis.\n\t\t\t\t\tBreast Cancer Res Treat.\n\t\t\t\t\t2015;\n\t\t\t\t\t151(2):\n\t\t\t\t\t443\u2013\n\t\t\t\t\t451.","DOI":"10.1007\/s10549-015-3413-4"},{"key":"2021080319422280700_i1543-2165-145-8-979-b12","doi-asserted-by":"crossref","unstructured":"Luna-More\n              S,\n            \n            \n              Casquero\n              S,\n            \n            \n              Perez-Mellado\n              A,\n            \n            \n              Rius\n              F,\n            \n            \n              Weill\n              B,\n            \n            \n              Gornemann\n              I.\n            \n          \n          Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast: review of 68 cases with follow-up of 54.\n\t\t\t\t\tPathol Res Pract.\n\t\t\t\t\t2000;\n\t\t\t\t\t196(1):\n\t\t\t\t\t35\u2013\n\t\t\t\t\t39.","DOI":"10.1016\/S0344-0338(00)80019-9"},{"key":"2021080319422280700_i1543-2165-145-8-979-b13","doi-asserted-by":"crossref","unstructured":"Varga\n              Z,\n            \n            \n              Zhao\n              J,\n            \n            \n              Ohlschlegel\n              C,\n            \n            \n              Odermatt\n              B,\n            \n            \n              Heitz\n              PU.\n            \n          \n          Preferential HER-2\/neu overexpression and\/or amplification in aggressive histological subtypes of invasive breast cancer.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2004;\n\t\t\t\t\t44(4):\n\t\t\t\t\t332\u2013\n\t\t\t\t\t338.","DOI":"10.1111\/j.1365-2559.2004.01843.x"},{"key":"2021080319422280700_i1543-2165-145-8-979-b14","doi-asserted-by":"crossref","unstructured":"Pettinato\n              G,\n            \n            \n              Manivel\n              CJ,\n            \n            \n              Panico\n              L,\n            \n            \n              Sparano\n              L,\n            \n            \n              Petrella\n              G.\n            \n          \n          Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2004;\n\t\t\t\t\t121(6):\n\t\t\t\t\t857\u2013\n\t\t\t\t\t866.","DOI":"10.1309\/XTJ7VHB49UD78X60"},{"key":"2021080319422280700_i1543-2165-145-8-979-b15","doi-asserted-by":"crossref","unstructured":"Hammond\n              ME,\n            \n            \n              Hicks\n              DG.\n            \n          \n          American Society of Clinical Oncology\/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline upcoming modifications: proof that clinical practice guidelines are living documents.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2015;\n\t\t\t\t\t139(8):\n\t\t\t\t\t970\u2013\n\t\t\t\t\t971.","DOI":"10.5858\/arpa.2015-0074-ED"},{"key":"2021080319422280700_i1543-2165-145-8-979-b16","doi-asserted-by":"crossref","unstructured":"Wolff\n              AC,\n            \n            \n              Hammond\n              ME,\n            \n            \n              Hicks\n              DG,\n            \n            et al.\n          \n          Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2014;\n\t\t\t\t\t138(2):\n\t\t\t\t\t241\u2013\n\t\t\t\t\t256.","DOI":"10.5858\/arpa.2013-0953-SA"},{"key":"2021080319422280700_i1543-2165-145-8-979-b17","doi-asserted-by":"crossref","unstructured":"Wolff\n              AC,\n            \n            \n              Hammond\n              MEH,\n            \n            \n              Allison\n              KH,\n            \n            et al.\n          \n          Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t142(11):\n\t\t\t\t\t1364\u2013\n\t\t\t\t\t1382.","DOI":"10.5858\/arpa.2018-0902-SA"},{"key":"2021080319422280700_i1543-2165-145-8-979-b18","doi-asserted-by":"crossref","unstructured":"Stewart\n              RL,\n            \n            \n              Caron\n              JE,\n            \n            \n              Gulbahce\n              EH,\n            \n            \n              Factor\n              RE,\n            \n            \n              Geiersbach\n              KB,\n            \n            \n              Downs-Kelly\n              E.\n            \n          \n          HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2017;\n\t\t\t\t\t30(11):\n\t\t\t\t\t1561\u2013\n\t\t\t\t\t1566.","DOI":"10.1038\/modpathol.2017.65"},{"key":"2021080319422280700_i1543-2165-145-8-979-b19","unstructured":"Yang\n              W,\n            \n            \n              Wei\n              B,\n            \n            \n              Chen\n              M,\n            \n            \n              Bu\n              H.\n            \n          \n          Evaluation of immunohistochemistry HER2 results interpretation in invasive micropapillary carcinoma of the breast [in Chinese].\n\t\t\t\t\tZhonghua Bing Li Xue Za Zhi.\n\t\t\t\t\t2015;\n\t\t\t\t\t44(1):\n\t\t\t\t\t48\u2013\n\t\t\t\t\t52."},{"key":"2021080319422280700_i1543-2165-145-8-979-b20","doi-asserted-by":"crossref","unstructured":"Hashmi\n              AA,\n            \n            \n              Aijaz\n              S,\n            \n            \n              Mahboob\n              R,\n            \n            et al.\n          \n          Clinicopathologic features of invasive metaplastic and micropapillary breast carcinoma: comparison with invasive ductal carcinoma of breast.\n\t\t\t\t\tBMC Res Notes.\n\t\t\t\t\t2018;\n\t\t\t\t\t11(1):\n\t\t\t\t\t531.","DOI":"10.1186\/s13104-018-3623-z"},{"key":"2021080319422280700_i1543-2165-145-8-979-b21","doi-asserted-by":"crossref","unstructured":"Kim\n              MJ,\n            \n            \n              Gong\n              G,\n            \n            \n              Joo\n              HJ,\n            \n            \n              Ahn\n              SH,\n            \n            \n              Ro\n              JY.\n            \n          \n          Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2005;\n\t\t\t\t\t129(10):\n\t\t\t\t\t1277\u2013\n\t\t\t\t\t1282.","DOI":"10.5858\/2005-129-1277-IACCOI"},{"key":"2021080319422280700_i1543-2165-145-8-979-b22","doi-asserted-by":"crossref","unstructured":"Yu\n              JI,\n            \n            \n              Choi\n              DH,\n            \n            \n              Park\n              W,\n            \n            et al.\n          \n          Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: matched case-control study.\n\t\t\t\t\tBreast.\n\t\t\t\t\t2010;\n\t\t\t\t\t19(3):\n\t\t\t\t\t231\u2013\n\t\t\t\t\t237.","DOI":"10.1016\/j.breast.2010.01.020"},{"key":"2021080319422280700_i1543-2165-145-8-979-b23","doi-asserted-by":"crossref","unstructured":"Wu\n              Y,\n            \n            \n              Zhang\n              N,\n            \n            \n              Yang\n              Q.\n            \n          \n          The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.\n\t\t\t\t\tBMC Cancer.\n\t\t\t\t\t2017;\n\t\t\t\t\t17(1):\n\t\t\t\t\t839.","DOI":"10.1186\/s12885-017-3855-7"},{"key":"2021080319422280700_i1543-2165-145-8-979-b24","doi-asserted-by":"crossref","unstructured":"Chen\n              H,\n            \n            \n              Wu\n              K,\n            \n            \n              Wang\n              M,\n            \n            \n              Wang\n              F,\n            \n            \n              Zhang\n              M,\n            \n            \n              Zhang\n              P.\n            \n          \n          Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis.\n\t\t\t\t\tCancer Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t6(12):\n\t\t\t\t\t2775\u2013\n\t\t\t\t\t2786.","DOI":"10.1002\/cam4.1227"},{"key":"2021080319422280700_i1543-2165-145-8-979-b25","doi-asserted-by":"crossref","unstructured":"Li\n              D,\n            \n            \n              Zhong\n              C,\n            \n            \n              Cheng\n              Y,\n            \n            et al.\n          \n          A competing nomogram to predict survival outcomes in invasive micropapillary breast cancer.\n\t\t\t\t\tJ Cancer.\n\t\t\t\t\t2019;\n\t\t\t\t\t10(27):\n\t\t\t\t\t6801\u2013\n\t\t\t\t\t6812.","DOI":"10.7150\/jca.27955"},{"key":"2021080319422280700_i1543-2165-145-8-979-b26","doi-asserted-by":"crossref","unstructured":"Lewis\n              GD,\n            \n            \n              Xing\n              Y,\n            \n            \n              Haque\n              W,\n            \n            et al.\n          \n          The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast.\n\t\t\t\t\tBreast J.\n\t\t\t\t\t2019;\n\t\t\t\t\t25(6):\n\t\t\t\t\t1171\u2013\n\t\t\t\t\t1176.","DOI":"10.1111\/tbj.13432"},{"key":"2021080319422280700_i1543-2165-145-8-979-b27","doi-asserted-by":"crossref","unstructured":"Wolff\n              AC,\n            \n            \n              Hammond\n              ME,\n            \n            \n              Schwartz\n              JN,\n            \n            et al.\n          \n          American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2007;\n\t\t\t\t\t131(1):\n\t\t\t\t\t18\u2013\n\t\t\t\t\t43.","DOI":"10.5858\/2007-131-18-ASOCCO"},{"key":"2021080319422280700_i1543-2165-145-8-979-b28","doi-asserted-by":"crossref","unstructured":"Sorscher\n              S.\n            \n          \n          Expanding definitions of HER2 positivity.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2018;\n\t\t\t\t\t31(4):\n\t\t\t\t\t685.","DOI":"10.1038\/modpathol.2017.141"},{"key":"2021080319422280700_i1543-2165-145-8-979-b29","doi-asserted-by":"crossref","unstructured":"Stewart\n              RL,\n            \n            \n              Gulbahce\n              EH,\n            \n            \n              Geiersbach\n              KB,\n            \n            \n              Downs-Kelly\n              E.\n            \n          \n          Reply to commentary on \u2018HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features'.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2018;\n\t\t\t\t\t31(4):\n\t\t\t\t\t686.","DOI":"10.1038\/modpathol.2018.28"},{"key":"2021080319422280700_i1543-2165-145-8-979-b30","doi-asserted-by":"crossref","unstructured":"Zhou\n              S,\n            \n            \n              Yang\n              F,\n            \n            \n              Bai\n              Q,\n            \n            et al.\n          \n          Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2020;\n\t\t\t\t\t33(7):\n\t\t\t\t\t1275\u2013\n\t\t\t\t\t1286.","DOI":"10.1038\/s41379-020-0461-z"},{"key":"2021080319422280700_i1543-2165-145-8-979-b31","doi-asserted-by":"crossref","unstructured":"Chibon\n              F,\n            \n            \n              de Mascarel\n              I,\n            \n            \n              Sierankowski\n              G,\n            \n            et al.\n          \n          Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO\/CAP and FDA recommendations.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2009;\n\t\t\t\t\t22(3):\n\t\t\t\t\t403\u2013\n\t\t\t\t\t409.","DOI":"10.1038\/modpathol.2008.195"},{"key":"2021080319422280700_i1543-2165-145-8-979-b32","doi-asserted-by":"crossref","unstructured":"Bartley\n              AN,\n            \n            \n              Washington\n              MK,\n            \n            \n              Colasacco\n              C,\n            \n            et al.\n          \n          HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t35(4):\n\t\t\t\t\t446\u2013\n\t\t\t\t\t464.","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"2021080319422280700_i1543-2165-145-8-979-b33","doi-asserted-by":"crossref","unstructured":"Hofmann\n              M,\n            \n            \n              Stoss\n              O,\n            \n            \n              Shi\n              D,\n            \n            et al.\n          \n          Assessment of a HER2 scoring system for gastric cancer: results from a validation study.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2008;\n\t\t\t\t\t52(7):\n\t\t\t\t\t797\u2013\n\t\t\t\t\t805.","DOI":"10.1111\/j.1365-2559.2008.03028.x"},{"key":"2021080319422280700_i1543-2165-145-8-979-b34","doi-asserted-by":"crossref","unstructured":"De la Cruz\n              C,\n            \n            \n              Moriya\n              T,\n            \n            \n              Endoh\n              M,\n            \n            et al.\n          \n          Invasive micropapillary carcinoma of the breast: clinicopathological and immunohistochemical study.\n\t\t\t\t\tPathol Int.\n\t\t\t\t\t2004;\n\t\t\t\t\t54(2):\n\t\t\t\t\t90\u2013\n\t\t\t\t\t96.","DOI":"10.1111\/j.1440-1827.2004.01590.x"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/8\/979\/2878777\/i1543-2165-145-8-979.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/8\/979\/2878777\/i1543-2165-145-8-979.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:39:15Z","timestamp":1764790755000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/8\/article-p979.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,11,19]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2020-0288-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}